Karp Capital Management Corp lifted its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 8.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,624 shares of the company’s stock after purchasing an additional 287 shares during the period. Karp Capital Management Corp’s holdings in Johnson & Johnson were worth $620,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. US Asset Management LLC bought a new position in shares of Johnson & Johnson during the third quarter worth approximately $30,000. Steward Financial Group LLC bought a new position in Johnson & Johnson during the 4th quarter worth $34,000. Jackson Wealth Management LLC increased its stake in Johnson & Johnson by 1.7% during the 3rd quarter. Jackson Wealth Management LLC now owns 16,959 shares of the company’s stock worth $40,000 after acquiring an additional 277 shares during the period. Iron Horse Wealth Management LLC increased its stake in Johnson & Johnson by 29.9% during the 4th quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company’s stock worth $45,000 after acquiring an additional 61 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. increased its stake in Johnson & Johnson by 290.7% during the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 293 shares of the company’s stock worth $47,000 after acquiring an additional 218 shares during the period. Institutional investors own 67.84% of the company’s stock.
A number of equities analysts have commented on the company. Raymond James raised their price objective on Johnson & Johnson from $185.00 to $195.00 and gave the stock an “outperform” rating in a research note on Thursday. Sanford C. Bernstein downgraded Johnson & Johnson from an “outperform” rating to a “market perform” rating and raised their target price for the company from $180.00 to $183.00 in a report on Wednesday, March 16th. StockNews.com started coverage on Johnson & Johnson in a report on Thursday, March 31st. They issued a “strong-buy” rating on the stock. The Goldman Sachs Group raised their target price on Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a report on Tuesday, April 12th. Finally, Morgan Stanley reduced their target price on Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 6th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $184.57.
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings data on Tuesday, January 25th. The company reported $2.13 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.12 by $0.01. Johnson & Johnson had a return on equity of 37.46% and a net margin of 22.26%. The company had revenue of $24.80 billion during the quarter, compared to the consensus estimate of $25.29 billion. During the same quarter in the prior year, the firm posted $1.86 earnings per share. The firm’s revenue was up 10.4% compared to the same quarter last year. Equities analysts anticipate that Johnson & Johnson will post 10.48 EPS for the current year.
In other news, VP Thibaut Mongon sold 23,681 shares of the company’s stock in a transaction that occurred on Thursday, March 17th. The stock was sold at an average price of $176.25, for a total value of $4,173,776.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.35% of the company’s stock.
Johnson & Johnson Profile (Get Rating)
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Levi Straus Stock Ready to Buy the Dip
- Bed Bath & Beyond Stock Ready to Scale Into
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.